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Abstract
Aim: To evaluate the prevalence of previously undiagnosed hepatitis C virus and associated
patient risk factors in an urban ED through a universal, integrated screening program, to
contextualize results found in terms of gaps in existing HCV screening models and to inform
future sustainable and effective screening models.
Methods: ED patients, ages 18-71, that were medically stable, hadn’t had a prior HCV test, and
were having blood drawn as part of routine clinical care, were offered (n=2,726) an anti-HCV test,
of whom 1,945 accepted. An assessment of correlates to anti-HCV positivity was completed using
a binomial logistic regression model.
Results: Approximately, 12.5% (n=241) of patients tested (n=1,923) were anti-HCV positive.
Among birth-cohort patients, 18.7% (n=154) tested positive. Specifically, holding all else constant,
patients within the birth-cohort were associated with odds of having anti-HCV positivity 13.1 (CI:
7.5-22.9) times higher than those born outside the birth-cohort. Notably, approximately 5.8%
(n=14) of patients who were anti-HCV positive had no documented risk factors. After controlling
for all other variables, anti-HCV positivity was associated with patients within the birth-cohort,
males, PWID, and persons living with HIV (PLWH).
Conclusion: The anti-HCV prevalence found in the JHBMC ED was high and comparable to that
documented in other urban EDs throughout the country. This study demonstrates the unique
capacity of EDs to reach previously missed or unacknowledged cases of hepatitis C. ED HCV
screening models should be further piloted and evaluated throughout the country, as they might
serve as critical safety-nets in the effort to curb this silent, costly epidemic.

Keywords: Hepatitis C; HCV; HCV testing, disease prevalence; undiagnosed infection;
emergency medicine; epidemiology; universal screening; targeted screening; CDC
recommendations; guidelines.
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INTRODUCTION

The mounting economic and societal burden caused by two distinct epidemics of hepatitis C
virus (HCV) infection poses a significant challenge in the United States (U.S.). Over 4.1 million
persons in the U.S. are estimated to be infected with HCV, of whom 3.5 million are predicted to
be chronically HCV-infected.1–3 Established, chronic infections mostly include persons born
during the years 1945 to 1965, and account for three-fourths (75%) of total HCV infections.4–6
This population, previously known as the post-transfusion population, is now referred to as the
baby boomer, birth-cohort and is characterized by a low risk of ongoing transmission.4,6,7 New
infections represent a markedly different epidemiologic profile and predominantly include
persons who inject drugs (PWID) and HIV-infected men who have sex with men (MSM).4,6,8,9

A new, acute HCV infection will spontaneously clear within roughly six months for
approximately 15%-25% of cases; thus, only 75%-85% of infections progress to a chronic
state.10–13 Once infection reaches a chronic state, disease path both varies in time and stage and
greatly depends a variety of fixed factors related to the host, virus, and environment (see Table
1).
Table 1. Natural history of chronic HCV infection: Host, viral and environmental
factors11
Host Factors

Viral Factors

Environmental Factors

Age at infection, gender, race, Viral load (RNA), genotype,

Caffeine, alcohol, smoking,

obesity, steatosis, insulin

coinfection with HIV,

cannabis

resistance, diabetes, genetics,

coinfection with HBV

ALT levels, exercise

Roughly 60%-70% of cases will progress from chronic HCV infection to chronic liver disease,
while 5%-20% will advance further to cirrhosis, and 1%-5% will die from hepatocellular
carcinoma (HCC), end-stage liver disease (ESLD), or due to complications arising from a liver
transplant.10,12
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Chronic HCV infection is the leading indication for HCC and the leading cause for both liver
transplants and liver failure in the U.S.14–17 Morbidity and mortality attributable to HCV
infection is expected to increase considerably over the next 50 years – so much so that at the
current rates of treatment, roughly 1.76 million people will develop cirrhosis and mortality from
HCV-associated complications will surpass 1 million.18 In fact, HCV-associated mortality
eclipsed that of HIV almost a decade ago, in 2007.19 A high HCV prevalence combined with the
severity of complications caused by chronic, long-term infection, constitutes a public health
crisis that demands attention.4,19–24

The increasing burden of HCV on the healthcare system coupled with recent breakthroughs in
the treatment of HCV infection have revitalized efforts to confront the HCV epidemic both in the
U.S. and globally and stimulated much enthusiasm for a long under-recognized and
unacknowledged patient population. Historically, HCV infection received little attention from
the public and government authorities. Less than 3% of funding allotted to HIV-related
initiatives is annually earmarked by the Centers for Disease Control and Prevention (CDC) for
viral hepatitis.25

HCV infection gained notoriety in 2014, when the U.S. Food and Drug Administration (FDA)
approved three effective, short-term (3-month) oral regimens that demonstrated sustained
virologic response in over 90% of cases across varying patient demographics. 26,27 Now, only two
years later, upwards of 10 similarly promising drugs have either now been approved for hepatitis
C treatment or are currently being channeled through the drug approval pipeline. 26,28,29

The concurrent passage and implementation of the Patient Protection and Affordable Care Act
(ACA), which mandated full coverage for recommended preventative services, such as HCV
screening, and eliminated payer ability to deny coverage to patients because of preexisting health
conditions, presented an opportunity to transform the HCV care cascade. 30,31 Despite these
advances, treatment remains elusive for the vast majority of the population due to pronounced
barriers within a fragmented care system.27,28,32–34
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Low rates of HCV screening and diagnosis remain one of the more significant barriers. Studies
have estimated that approximately 45%-85% of those infected with chronic HCV are unaware of
their serostatus.4,6,7 Limited, spotty screening also contributes to countless missed opportunities
for medical evaluation, counseling and education, care, and treatment. 21,33,35,36 In fact, increased
HCV-related morbidity and mortality have been partially attributed to historically low screening
rates and a lack of patient education surrounding the disease. 34,37–39

Episodic care settings, specifically emergency departments (EDs), could be a valuable point of
intervention, given the high proportion and visit frequency of patients that are high-risk for HCV
infection and from medically underserved populations (PWID, uninsured persons, mentally-ill,
homeless, Medicaid recipients).38,40–43 Thus, urban EDs might serve as a critical safety net in
reaching individuals unaware of their infection.42,44,45 Prevalence of HCV antibody seropositivity
in some urban EDs has been demonstrated to be as high as 13% - 18%.44,46–48

Further characterizing the population affected by HCV within EDs is a critical first step that can
be used to analyze, guide, and motivate screening and policy efforts. In this study, we evaluated
the prevalence of previously undiagnosed hepatitis C virus and associated patient risk factors in
an urban ED through a universal, integrated screening program. The results of this study will
serve to more accurately assess community need and gaps in existing screening models,
investigate the feasibility of screening implementation in an ED setting, and inform future
sustainable and effective screening models.

METHODS
Setting

This study was conducted in the adult ED of Johns Hopkins Bayview Medical Center (JHBMC)
in Baltimore, Maryland. JHBMC serves a socioecomically-disadvantaged, diverse population
with a high prevalence of HIV and injection drug use (IDU).49,50 Among all urban cities,
Baltimore has the highest per capita prevalence of PWID of persons aged 15-64 years.50 Annual
ED census averages approximately 60,000 patients. Of those patients JHBMC serves, 35%
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identify as black, 55% identify as white, 7% identify as Hispanic, and 53% identify as female.
With respect to payer mix, approximately 13.2% of the population was uninsured, 30.2% had
private insurance, and 53.6% had public insurance. This study was approved by the Johns
Hopkins University School of Medicine Institutional Review Board.

Study Design

This was a descriptive analysis of the results of an integrated, non-targeted (universal) HCV
screening program from August 2016 to October 2016 at a single-center ED. The study was
cross-sectional in design with retrospective analysis of the EMR for demographics and an
assessment of risk factors for HCV. Hepatitis C screening, instituted through the EMR as a
recommended clinical policy, was both triage-based and nursing-driven.

ED patients ages 18-71 were eligible for HCV screening if (1) they were having blood drawn as
part of their clinical visit, (2) had never been previously tested for hepatitis C within the Johns
Hopkins Health System, and (3) by triage nurse assessment. Patients unable to provide informed
consent due to altered mental status or severe, debilitating illness were excluded. Patient consent
was obtained utilizing an opt-out approach and documented in the EMR. The opt-out consent
policy required patients to verbally inform nursing staff if they did not want a test. This
screening strategy was demonstrated to be less stigmatizing and more effective in routine HIV
screening programs implemented across various health settings.51,52

Tests were electronically ordered by the triage nurse for consenting patients and then cosigned
by physicians. ED nursing and technician staff obtained blood specimens along with other
clinical samples and submitted them to the hospital laboratory for processing. All screening tests
were analyzed on the Abbott Architect with an anti-HCV assay using chemiluminescent
microparticle immunoassay (CMIA) technology, which has a specificity of 99.6% and sensitivity
of 99.1%.53 Laboratory staff phoned research program personnel in the event of a positive result.
If still receiving care in the ED, patients were informed at bedside by the clinical team in
cooperation with research staff. Discharged patients were called, notified of the result, and where
appropriate, offered help in following-up with a specialist or primary medical provider (PMD).
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Data Collection

Basic demographic and clinical data were abstracted from administrative, programmatic, or
clinical datasets to establish a comprehensive study-related database by trained research staff.
Any patients screened were assigned a unique study code. Patient identifiers were permanently
removed to adhere to protected health information standards. Source documentation, including
paper laboratory reports and documents containing identifiable patient information, was kept in a
locked filing cabinet in a secluded departmental research suite. All research staff received
standardized training both in chart review and related to EMR (Epic Systems) navigation prior to
collecting any data. Research staff conducted periodic systematic reviews of data to ensure
validity, and any discrepancies were corrected and verified by both senior research staff and the
principal investigator.

Data Management

The primary outcome of the study was HCV antibody (Ab) seropositivity, which was defined as
a positive antibody test result performed between August and October 2016. Major independent
variables were HIV seropositivity and IDU, established risk factors of HCV Ab positivity, and
year of birth, specifically those born between 1945 and 1965. HIV seropositivity was defined by
a positive HIV laboratory result or confirmatory provider note documented within the medical
record. IDU was defined as having ever injected drugs. Gender was characterized as male or
female. Race was accounted for as Black or non-Black. Risk factors such as transfusion history,
transplant, tattoos, ALT elevation, and incarceration were not reliably available within the EMR
and were not included in this analysis.

Statistical Analysis

Descriptive statistics characterized the study population. Proportions were tabulated using chisquare tests, and a binary logistic regression model captured factors associated with HCV Ab
seropositivity. Any P-value <0.05 (95% confidence) was considered to be significant and
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included within the final model. Results were analyzed using the SPSS software (IBM Corp.
Released 2011. IBM SPSS Statistics for Mac, version 20.0. Armonk, NY, USA).

RESULTS

During the three months of the study period, total ED visits were 13,261. Of the population,
3,468 (~26%) patients were excluded based on age criteria (under 18: 344, ~2.6%; 72+: 3,124,
~23.6%). Of patients between 18-71 years of age, approximately 34.6% (3,384) were excluded
because no blood was drawn as part of routine clinical care during the patient’s ED visit. Of
patients within the eligible age-range and having blood drawn as part of routine clinical care,
nearly 44.4% (2,844) were excluded because they a prior HCV test [HCV antibody screening or
HCV Quantitative PCR (RNA)] documented within the EMR, while roughly 13.1% (839) of
patients were excluded due to having an altered mental status or being medically unstable during
time of test offer.

In all, 2,726 patients, or 20.6% of the total ED population, were offered HCV screening. Only
781 (28.6%) declined the test offer, and 1,945 (71.4%) accepted. Approximately 22 tests were
cancelled because the blood sample was either not collected or determined insufficient for
analysis. In total, 1923 patients, 70.5% of those offered screening, received a HCV Ab test (antiHCV test). All tests were free of charge.

Of those who received tests, 50.5% were female and 49.5% were male; 39.3% were black and
60.4% were non-black. Among the 1,923 patients tested, 241(12.5%) were anti-HCV positive.
For patients born during the years 1945-1965, known as the birth cohort, 154 of 822 (18.7%)
patients tested positive. Prevalence among patients born before or after the birth cohort years was
7.8% (87 of 1106). Of patients who had ever injected drugs, 92.7% were found to be anti-HCV
positive. Of patients with HIV, 83.3% were found to have reactive test results.

Table 1 presents results from both univariate analyses as well as adjusted binomial regression
model. In the univariate analysis, being born in the birth-cohort was associated with a 2.7 (CI:
2.0-3.6) increase in the odds of anti-HCV positivity. Ever having injected drugs was associated
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with a 170.2 (CI: 84.3-343.4) higher odds of anti-HCV positivity. Having a HIV infection was
associated with a 38.1 (CI: 12.9-112.4) increase in odds of anti-HCV positivity. Being male was
associated with a 4.1 (CI: 3.0-5.7) increase in odds of HCV antibody infection.

In the final model, controlling for all variables, anti-HCV positivity was associated with patients
within the birth-cohort, males, PWID, and persons living with HIV (PLWH). Specifically,
holding all other covariates constant, patients within the birth-cohort were associated with odds
of having anti-HCV positivity 13.1 (CI: 7.5-22.9) times higher than those born outside the birthcohort. Only 14 of the 251 (5.8%) of patients who were anti-HCV positive had no risk factors
documented, including IDU, age, or HIV seropositivity. Within the final model, 51% of the
variance within the results was explained. The Hosmer-Lemeshow test verified goodness of fit.

DISCUSSION
HCV Prevalence

The overall undocumented HCV prevalence found in this study (12.5%) is significantly higher
than national prevalence estimates, but mirrors the findings of several studies conducted locally
in Baltimore and in academic EDs across the country.

National prevalence estimates of chronic HCV infection predominantly rely on the data from the
U.S.-based National Health and Nutrition Examination Surveys (NHANES). The most recently
released analysis, from the years 2003 through 2010, estimated that 3.2 million individuals, 1.3%
of the total U.S. population, are currently living with chronic HCV.7,54 HCV prevalence was
reported by previous NHANES studies to be 1.6% between 1999 and 2003 and 1.8% between
1988 and 1994, and appeared to be declining.1,55

Yet, NHANES analyses are widely considered to be underestimates of the true HCV prevalence
in the U.S, due to limitations related to sampling bias. The NHANES HCV prevalence survey
only collects blood serum samples from the non-institutionalized population in the U.S, thereby
excluding certain high-risk, transient populations, which include the incarcerated, the homeless,
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nursing home residents, persons on active military duty, and immigrants. 6,7 Moreover, studies
have shown that chronic HCV disproportionately affects some of these very populations: it has
been documented at elevated rates in the mentally ill (19%) 56–58, the incarcerated (23%41%)6,59,60, PWID (58%)6, and the homeless (22%-53%).6

Thus, a more accurate prevalence is projected to be between 5.2 and 7.1 million chronically
HCV-infected persons (~3% of the U.S. population). 6,61 However, even this updated prevalence
estimate is noticeably lower than the one found in our study.

Comparatively, many studies conducted locally in Baltimore, as well as analyses undertaken in
urban EDs across the country, found similarly high prevalence rates of HCV infection. A
screening program in sexually-transmitted infection (STI) clinics run by the city health
department in Baltimore, Maryland recently found a 7% overall HCV prevalence and a 30%
prevalence among persons in the birth cohort.62 Another Baltimore study reported an overall
anti-HCV prevalence of 15% with age, IDU history and male sex associated with HCV Ab
positivity.63 In EDs across the country, prevalence rates have been documented across a
relatively wide range: 1.6% (RHI, Providence); 11.6% (UAB, Birmingham); 12% (BMC,
Boston); 14% (UC, Cincinnati); 7.3% (NYU, New York); and 10.3% (AHS, Oakland). 64–69

Our study found a HCV infection prevalence of 18.7% within the birth cohort. Nationally, the
birth cohort’s HCV prevalence is estimated to be 3%-4%, or three to five-fold any other age or
age-group.7,70 Further, published studies demonstrate HCV antibody positive prevalence among
this age-group to be upwards of 10% and as high as 30%.59,62,71–74 A recent study in an Alabama
emergency department found an 11.1% seropositivity in the baby boomer birth-cohort via an optout screening program73, while a study on U.S. male veterans living in Atlanta reported a 15%
seropositivity among birth-cohort veterans that had not previously been screened for HCV.71
Another study on veterans indicated an overall 10.3% seropositivity rate among the birth-cohort
compared to 1.2% among veterans born after 1965.72 Further, an analysis of a screening program
in New York jails found a 22.5% seropositivity in the birth-cohort compared to 18.5%
seropositivity in those born after 1965.59 Thus, similar to the rate of total undocumented HCV
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seropositivity within the JHBMC ED, our prevalence finding for the birth-cohort was higher than
in most published studies.

Among PWID, we found a slightly higher HCV prevalence of 92.7%. Previously published
studies on HCV infection among PWID report prevalence rates ranging from 38% to as high as
85%, with as many as 75% of injection drug users unaware of their anti-HCV
seropositivity.48,62,67,75–78 In the JHBMC adult ED, IDU prevalence is estimated to be 6.9%+,
while HCV seroprevalence is estimated to be roughly 15%. These estimates parallel what has
been reported at our sister institution’s ED, Johns Hopkins Hospital (JHH) ED, in terms of IDU
prevalence (7%+) and HCV seroprevalence (13.8%, 2013 and 18%, 1992).47,48 Hence, a
minimum of 12.6% (115/ [6.9% of 13,261]) of anti-HCV positive, documented PWID are
unaware of their status in our ED. This projection is reported as a minimum, as any number of
anti-HCV positive PWID that previously tested negative within the Hopkins system are excluded
from the assessment, along with those who present to the ED with a drug overdose and are
consequently indicated to be medically unstable and ineligible for testing. Further, this study
relies on IDU history of the patient population to be accurately documented within the medical
record, increasing the likelihood that this projection is an underestimate.

HCV Screening Recommendations

The most recent guidelines from the CDC were issued in 2012 and recommend risk-based
hepatitis C testing, which includes: PWID or having ever injected drugs; hemodialysis patients;
the post-transfusion population; transplant patients; persons with clotting disorders; persons
subject to occupational exposures; PLWH; those with an abnormal alanine aminotransferase
level; and those born to a HCV-infected mother, and targeted, once-in-a-lifetime testing for
persons born during the years 1945-1965, the birth-cohort.4 From 1998-2011, the CDC had only
advised a risk-based testing strategy.79 A year later in 2013, the U.S. Preventive Services Task
Force (USPSTF) assigned a B-grade recommendation to targeted, once-in-a-lifetime HCV
testing for the birth-cohort.20,21 This rating allowed PMDs and providers within episodic care
settings, such as hospitals, to receive reimbursements for HCV screening and fortified the need
for prevention-focused, patient-centered HCV care.
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Following the release of the new CDC guidelines and associated-USPSTF policy, much
discussion focused on (1) effective implementation of these screening recommendations and (2)
the healthcare system’s infrastructure and capacity to manage and sustain HCV-related care for
newly diagnosed or informed populations. Accordingly, questions on which healthcare settings
were most appropriate and capable of establishing effective, integrated HCV screening protocols
arose. PMDs, rehabilitation and detoxification programs for persons suffering from substance
use disorders, and STI clinics were widely determined to be acceptable practices for HCV
screening initiatives.61

Feasibility of HCV Screening Implementation in the ED Setting

Mandates for public health, preventive-care focused initiatives, such as HCV screening, piloted
in the ED setting remain highly controversial at both the provider and policy level. As
demonstrated with HIV testing interventions, EDs are uniquely capable of reaching high-risk
(PWID, homeless, formerly incarcerated, mentally ill) or underserved, socioeconomicallydisadvantaged populations with previously undiagnosed infections who could seek treatment
once aware and educated about their serostatus.40,41,45,80,81 Moreover, these populations
disproportionately affected by HCV are less likely to be consistently monitored in by a PMD or
other outpatient care provider, and more apt to sporadically visit emergent or high-acuity care
settings.30,82,83

Urban EDs across the country have demonstrated the success and feasibility of differing
integrated HCV screening models, ranging from targeted, birth-cohort screening, to universal
screening paradigms, to risk-based only screening. These EDs have also reported varying levels
of success in identifying undocumented or undiagnosed infection and pursuing subsequent
linkage-to-care efforts for anti-HCV positive patients.

Our study implemented universal, once-in-a-lifetime screening and discovered a previously
undocumented 12.5% anti-HCV positivity. If we had only implemented targeted screening in the
birth cohort, 36% of cases would have remained undetected. Even when combining targeted,
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birth-cohort screening and risk-based screening models, 5.8% of cases would have been missed.
These findings are similar to those found by a mid-western ED, where 28% of reactive cases
were outside of the birth cohort and 7% had no apparent, documented risk factors.67 Likewise, an
ED in Oakland, Calif. found a similarly high prevalence (2.6%) among persons at no perceived
risk, and one in Rhode Island found that half of cases would have been missed if only current
screening recommendations were implemented.64,68

The changing epidemiologic profile of HCV infection, especially within the context of both
acute cases and incident cases of chronic HCV, also impacts the relative success and costeffectiveness of screening models. In fact, incidence of acute HCV infection has been increasing
since 2006 and as of 2014, is estimated to reach ~30,500 cases annually.5,70,77,84 These incident
cases are predominantly among PWID and HIV-infected MSM.8,9,29,77,84,85 Given the worsening
epidemic of PWID, especially among white persons who have previously used opioid agonists,
acute HCV incidence is expected to continue increasing. 10,77,86–88 If these trends endure, EDs
employing a targeted, birth-cohort screening strategy would miss these new cases. This becomes
increasingly worrisome when considering over two-thirds of PWID are unaware of their antiHCV positive status.76,89–91

Further, EDs that choose to implement targeted screening for patients within the birth-cohort
alone might also find lower acceptance rates as persons within this age group have been found to
misunderstand or unreliably report risk.4,7,38 Similarly, risk-based screening initiatives that single
out PWID might result in patients inaccurately reporting risk, due to fears of societal stigma that
surrounds these populations.8,76

Despite the successful, routine adoption of HCV screening in various academic, urban EDs,
support for these types of initiatives among emergency providers is mixed. EDs are already
chronically overcrowded, overburdened, and struggle to provide time-sensitive care for patients
presenting with acute illness.92–94 Recently, the Centers for Medicare and Medicaid Services
(CMS) sided against HCV testing models implemented in the ED setting, releasing a thorough
policy that precluded secondary care settings, with specific reference to EDs, from receiving
reimbursement for HCV screening.95 53.6% of the patient population that JHBMC’s ED serves
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has public or government-sponsored insurance; therefore, implementing any sustainable
screening program would warrant CMS reimbursement. The same proves true for EDs across the
country.

Even if EDs are able to implement a screening methodology, patients are likely to require
resource-intensive assistance in navigating care and accessing treatment options.28 Many patients
infected with HCV are likely to have alcohol and substance use disorders, competing health
priorities such as mental illness or homelessness, and limited social support; thus, linkage-to-care
might prove time-intensive and difficult.96–98 Linkage to specialty care rates vary widely, with
some programs reporting levels as low as 25% and others reporting levels as high as 80%. 28,62

Higher linkage-to-care rates were seen by hospitals, primary care centers, and EDs with
additional staff support, often in the form of a program coordinator, financial assistance
counselor, or nurse case manager.62,99–102 Without financial assistance in the form of external
funding, similar to the Ryan White comprehensive care model for HIV-infected persons,
ancillary staff dedicated to this type of initiative would not be feasible for the common ED, and
any additional workload heaped upon existing personnel might prove overwhelming.

Importance of Investing in Enhanced HCV Screening Models
Expert healthcare economists note HCV-related burden to be of increasing concern.56–58 Because
of the decades-long, asymptomatic incubation period of the virus, the healthcare system has only
begun to feel the true impact of the large prevalence of chronic HCV. 18 As the HCV-infected
baby boomer population ages, liver disease severity increases substantially, resulting in more
complications and increased healthcare utilization.17,18,42,58,103 Hospital diagnoses of HCV-related
complications, such as cirrhosis and HCC, have increased along with HCV-related inpatient
mortality.56–58 Several studies have also noted that both lack of insurance or governmentsponsored insurance are indicators of higher ED utilization, increased disease severity, length-ofstay and inpatient mortality.103–105 This is significant because chronic HCV is widely considered
to be “a disease of the marginalized”.106,107
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Total burden of disease in the U.S. is estimated to be $6.5 billion, and is anticipated to peak at
$9.1 billion in 2024.56,58 Peak costs are largely attributable to complications and care of persons
with advanced liver diseases such as decompensated cirrhosis (46%), compensated cirrhosis
(20%), and HCC (16%).56 Lifetime cost per patient was calculated as $64,490 ($46,780-$73,190)
in 2011, and is estimated to increase to $205,760 ($154,890-$486,890) in coming years due to
the influence of medical inflation.61
Hospitalizations and mortality are also increasing.42,90,103,108 Total hospitalizations for HCVrelated disease increased 190% from 2004 to 2011 alone.90 Annual HCV-related mortality has
been reported to be anywhere from 19,000109 to 80,00034 and is forecasted to increase to over
36,000 between 2022 and 2035.18,19,56
Increasing annual treatment of patients four-fold, to 400,000 – from the 100,000 that have been
treated historically – has been estimated to prevent over half a million cases of cirrhosis and over
250,000 HCV-associated deaths over the next decade.33 Most health economists agree that as
long as HCV prevalence is >0.84 and total costs amount to less than $50,000 per quality adjusted
life year (QALY), screening is cost-effective.22 Screening adults aged 20-69 (60% of persons) on
a population level was shown to be cost-effective by a recent analysis as 7.1% of liver-related
deaths were averted. This is an additional 3.8% of deaths averted than if only risk-based
screening was implemented.110 This expanded on previous cost-effectiveness analyses that have
demonstrated the value of a targeted, birth-cohort screening model.22,111

Notable Barriers to HCV Treatment

Numerous barriers along the cascade of HCV care prevent patients from receiving treatment, in
addition to challenges related to screening and diagnostics. The general inaccessibility and
rationing of treatment, an insufficient body of trained providers and a marginalized patient
population are the most enumerated barriers impeding progress.25,112
Drug prices are perhaps the most publicized barrier. Gilead Sciences and AbbVie, the two
pharmaceutical companies responsible for developing the first HCV drugs released, established
high fee structures for standard (12-week) regiments that ranged from $51,000 to $147,000.113–
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Proprietary licensing on their discoveries provided them with limited market competition, and

federal oversight on pharmaceutical drug pricing allowed them to inflate rates. While
government payers such as Medicaid and Medicare and private insurers do not pay ‘list’ prices
for treatment, cost per patient is still estimated to be high, at a minimum of ~$40,000 in 2014 and
~$30,000 in 2015.114–116

Payers overwhelming responded to these pricing models by severely rationing care in the U.S.
Eligibility for HCV treatment is primarily limited to those with either advanced stages of
cirrhosis (stage F4) or fibrosis (stage F3) and those without ongoing substance use
problems.26,115,116 Criteria for coverage vary considerably among payers and do not conform to
the treatment guidelines developed by the American Association for the Study of Liver Diseases
(AASLSD) and the Infectious Diseases Society of America (IDSA). 26,117,118 Medicaid is
especially limiting, with 88% of states authorizing specific eligibility criteria related to substance
use; 50% of these state policies required patients to remain abstinent for over 1 year in order to
receive treatment. These restrictions were neither mandated by the FDA nor supported by
scientific evidence.107,116 Moreover, in two-thirds of states, Medicaid demands that treatment be
provided by a specialist in infectious disease or gastroenterology. The result of these policies is a
growing bottleneck of patients without access to an already limited pool of specialists.

Payers have also introduced a broad range of other policy barriers that include requiring
clinically irrelevant laboratory standards, denial of coverage to HIV co-infected patients, an
evaluation of a patient’s pharmacy refill records to assess ‘patient readiness’ for care, contracts
for a once-in-a-lifetime course of therapy, and restrictive limits on enrollment volumes at
company-sponsored patient assistance programs.114,116,119 Ultimately, only a small minority of
patients are eligible for and eventually complete HCV-treatment. One systematic review,
analyzing recent studies on HCV treatment, concluded that treatment was prescribed to only 16%
of HCV-infected persons among the non-institutionalized U.S.population.28,106

Furthermore, only 56% of the individuals who underwent HCV-treatment achieved a sustained
virologic response (SVR), which is considered to be a functional cure.28 In response to criticism
and payer rationing, Gilead’s Sovaldi and Harvoni wholesale acquisition costs were reduced by
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nearly half in early 2015, resulting in a net $54,000 and $45,000 per treatment regiment,
respectively.113,114 Even with these price reductions, completing a full course of therapy still can
cost $100,000 per patient, given physician, facility and other care-related fees. Luckily, there is
hope for the future, as several new competitors have recently entered or are expected to enter the
market.113

Moreover, patient and provider-related beliefs, education, and practices profoundly impact
whether a patient pursues and completes treatment. Studies have found that most PMDs have
insufficient knowledge regarding screening for anti-HCV and chronic HCV infection and a
limited understanding of disease progression to HCC and ESLD.25,96 Additionally, many
healthcare professionals providing preventative services to patients have misconceptions of HCV
risk factors and natural history, and a limited awareness of the screening recommendations for
HCV infection.96,112,120

Additionally, in one study, more than half of physicians surveyed in the primary care setting
neglected to discuss stigmatized, high-risk behaviors such as IDU with their patients.120 Finally,
despite the availability of PMD training programs on HCV therapies, few primary care centers
actively offer HCV treatment to their patients, choosing instead to refer out to a limited pool of
overburdened specialists.121,122

Patient-level factors are also significant barriers to receiving treatment. Limited patient
knowledge and understanding of the disease, concerns related to side-effects, duration, and cost
of treatment, and lack of provider trust have all been documented as great obstacles for
treatment.27,121 These studies reinforce the need for additional staffing resources and
government-facilitated training initiatives for settings implementing HCV screening programs to
assure thorough and accurate counseling of anti-HCV positive patients and their respective
PMDs.
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Limitations

While there is no certainty that the high HCV prevalence found in this study and in other studies
discussed is generalizable to EDs across the country or even within similar regions, evidence
suggests HCV prevalence remains high and endemic in all EDs, with the exception of those in
extremely rural areas.67 Because our study evaluated prevalence among a specific subset of
patients (individuals between 18-71 having blood drawn as part of routine clinical care,
medically stable, with no prior HCV test in their medical history) the results are not
generalizable to other EDs. Limitations of this study include potential sampling bias as the
population inherently likely to visit an ED is more likely to be sick and have multiple
comorbidities.40,43 Participation bias is also a possibility as those at risk may have been less
likely to report risk or accept screening when offered. Moreover, the presence or absence of risk
factors included within the study was dependent on documentation in the form of a lab result or
provider note in the EMR; thus, the rates reported may be underestimates. Further, the sample
size of this study may be too small to fully assess the association of IDU and HIV with anti-HCV
positivity. As mentioned above, the generalizability of this study is uncertain, as other EDs may
serve differing demographics. Baltimore is particularly noted for its high prevalence of HIV,
HCV, and IDU. Finally, the prevalence findings of the study do not reflect total ED HCV
seroprevalence, as persons with HCV infection already documented within the EMR as well as
those who were previously screened were not offered a test.

Conclusion

In summary, HCV screening initiatives in EDs may prove particularly adept at identifying
previously undiagnosed HCV infection and help close the gap between persons infected and
persons accessing treatment. The high documented prevalence (1.6%-12%) and seroprevalence
(13-18%) in EDs, as well as the high prevalence of undiagnosed infection (12.5%) characterized
in this ED-based study, demonstrate the benefit of adopting an HCV screening strategy, more
specifically a universal or targeted, birth-cohort screening model. Universal screening models are
likely be perceived as less stigmatizing and have been demonstrated to be cost-effective at the
population-level.
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However, in order for HCV screening initiatives to be sustainable in the long-term in the ED
setting, CMS regulations must be amended to include reimbursement for secondary, episodic
care settings. Further, health care systems and providers must advocate for public funding
umbrellas, similar to the Ryan White comprehensive care model developed for HIV services, so
that hospitals, PMDs, and EDs may invest in ancillary personnel that can subsequently be trained
to educate patients and provide linkage to primary or specialty care assistance. Without enhanced
and more comprehensive screening, the economic and societal burden of HCV-related disease
will continue to increase, a fact especially troubling given the availability of an effective,
tolerable cure.

coding
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APPENDIX
Table 1. Factors associated with HCV antibody positivity
Characteristic
Number screened: HCV Prevalence (%)
Age
Non-Birth Cohort
1106
87 (7.86)
Birth Cohort
822
154 (18.73)

OR

(95% CI)

Adjusted OR

(95% CI)

2.70

(2.04-3.57)

13.12

(7.52-22.90)

Gender
Female
Male

973
955

54 (5.55)
187 (19.58)

4.14

(3.02-5.69)

0.37

(0.25-0.54)

Race
Black
Non-Black

758
1170

111 (14.64)
130 (11.11)

0.73

(0.56-0.96)

2.13

(1.46-3.12)

HIV Status
Negative
Positive

1904
24

221 (11.61)
20 (83.33)

38.10

(12.90-112.42)

0.13

(0.02-0.87)

Ever IDU
No
Yes

1804
124

126 (6.98)
115 (92.74)

170.17

(84.32-343.41)

0.002

(0.001-0.005)
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